Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$1.48 USD
+0.21 (16.54%)
Updated Sep 25, 2025 04:00 PM ET
After-Market: $1.46 -0.02 (-1.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ABOS 1.48 +0.21(16.54%)
Will ABOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ABOS
12 Health Care Stocks Moving In Thursday's Intraday Session
NR7 appears for ABOS after 3.25% move
ABOS forms Stochastic Reached Oversold on September 24
Technical picture remains unchanged for ABOS after it rises 1.59% on September 22
Is ABOS primed for downward momentum? 180 Bearish Setup shows up after sliding 4.55%